Results 71 to 80 of about 8,038 (216)

Update on Pediatric asthma management: Recent advances

Pediatric Allergy and Immunology, Volume 37, Issue 9, September 2026.
Pathophysiology of asthma: an opportunity for personalized targeted therapeutics. Abstract Asthma remains the commonest chronic pediatric respiratory disease and a major cause of childhood morbidity worldwide. Recent advances in pediatric asthma management shift the focus from symptom relief alone towards early control of airway inflammation ...
Nitin Dhochak, Polly F. M. Robinson, Sejal Saglani   +2 more
wiley   +1 more source

Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence‐Based Expert Review

International Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 852-879, August 2026.
ABSTRACT Background Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disease associated with significant morbidity. Systemic corticosteroids (SCS) are commonly prescribed for their anti‐inflammatory effects, but cumulative exposure carries risks, including metabolic, cardiovascular, and skeletal complications.
Andrew Thamboo, Deanna Gigliotti, Eugenio De Corso, Stella Lee, Benjamin S. Bleier, Christopher J. Chin, Marie‐Noelle Corriveau, Valerie Hox, Claire Hopkins, Peter H. Hwang, Arif Janjua, Ludger Klimek, Daniel Lee, John Lee, Amber Luong, Geoffrey Mortuaire, Joaquim Mullol, Zara M. Patel, John Scott, Doron Sommer, Leigh Sowerby, Marc Tewfik, Beatrice Voizard, Martin Wagenmannm, Sarah K. Wise, Jonathan Yip, Quirina Thompson, Martin Desrosiers, Yvonne Chan   +28 more
wiley   +1 more source

Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis

Nature Communications
Eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma (SEA) share a Type 2 (T2) inflammatory signature but exhibit distinct pathophysiology.
Cong Dong, Bingtai Lu, Changhao Zhong, Changxing Ou, Xiaojing Yang, Lingwei Wang, Xiaoyu Zuo, Lingna Xue, Chenyang Lu, Shang Wang, Junjie Wen, Jianjuan Ma, Zhenan Deng, Yiyi Liu, Liuheyi Ma, Ming Liu, Andrew M. Lew, Manali Mukherjee, Parameswaran Nair, Nanshan Zhong, Rongchang Chen, Zhanghua Chen, Yuxia Zhang, Qingling Zhang   +23 more
doaj   +1 more source

Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1710-1717, August 2026.
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis characterized by eosinophilia, asthma, and ear, nose, and throat (ENT) involvement. Although glucocorticoids (GCs) are effective in controlling symptoms, relapses and GC dependence are common. The aim of this study was to develop predictive models for vasculitis
Matthias Papo, Pauline Martinot, Renato A. Sinico, Vítor Silvestre‐Teixeira, Nils Venhoff, Maria‐Letizia Urban, Michele Iudici, Juliane Mahrhold, Francesco Locatelli, Giulia Cassone, Franco Schiavon, Benjamin Seeliger, Thomas Neumann, Claudia Feder, Matthieu Groh, Chiara Marvisi, Maxime Samson, Thomas Barba, David Jayne, Arianna Troilo, Jens Thiel, Bernhard Hellmich, Sara Monti, Carlomaurizio Montecucco, Carlo Salvarani, Jean‐Emmanuel Kahn, Bernard Bonnotte, Cécile‐Audrey Durel, Xavier Puéchal, Luc Mouthon, Loïc Guillevin, Giacomo Emmi, Augusto Vaglio, Raphaël Porcher, Benjamin Terrier, on behalf of the French Vasculitis Study Group and the Eosinophilic Granulomatosis with Polyangiitis European Study Group   +35 more
wiley   +1 more source

Targeting the interleukin-5 pathway in EGPA: Evidence, uncertainties and opportunities

, 2022
Only a minority of patients with eosinophilic granulomatosis with polyangiitis (EGPA) can be weaned-off glucocorticoids (GC) using conventional treatment strategies.
Vaglio A., Del Giacco S., Berti A., Atzeni F., Salvarani C., Emmi G., Dagna L.   +6 more
core   +1 more source

Healthcare Resource Utilisation and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Analysis of German Insurance Claims Data

Rheumatology and Therapy
Introduction Evidence is limited on the clinical and economic burden of eosinophilic granulomatosis with polyangiitis (EGPA) in Europe. We evaluated EGPA healthcare resource utilisation (HCRU), days off work, and costs in Germany.
Paul Dolin, Anat Shavit, Jennifer Rowell, Chris Edmonds, Josefine Persson, Danuta Kielar, Keltie McDonald, Antje Mevius, Bernhard Hellmich, Stephanie Y. Chen   +9 more
doaj   +1 more source

Prevalence, incidence and healthcare burden of eosinophilic granulomatosis with polyangiitis in the UK

ERJ Open Research
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease characterised by the combination of small-to-medium vessel vasculitis, blood and tissue eosinophilia, and asthma and/or sinonasal disease.
Jeremiah Hwee, Lorraine Harper, Qinggong Fu, Krishnarajah Nirantharakumar, George Mu, Rupert W. Jakes   +5 more
doaj   +1 more source

Immunological and epithelial barrier dysfunction in EGPA: the possible role of new biomarkers [PDF]

Exploration of Asthma & Allergy
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis with heterogeneous clinical manifestations. Identifying reliable biomarkers is crucial to predicting disease evolution and guiding therapy.
Cristiano Caruso, Ilaria Baglivo, Stefania Colantuono, Maria Antonietta Zavarella, David Longhino, Chiara Laface, Laura Bruno, Gabriele Lucca, Fabio Romano Selvi, Eleonora Di Carluccio, Gabriele Ciasca, Umberto Basile, Benedetta Niccolini, Mario Rigante, Eugenio De Corso, Antonio Gasbarrini, Giovanni Battista Capoccetta, Paola Anselmi, Aikaterini Detoraki, Elisabetta Greco, Benedetta Bondi, Vincenzo Patella, Stefano Del Giacco   +22 more
doaj   +1 more source

257.. Evidence of ultrasound subclinical atherosclerosis in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

, 2022
Background: Atherosclerosis is a multifactorial chronic inflammatory process involving the innermost layer of arteries. In addition to traditional risk factors, non-traditional ones, such as systemic inflammation and endothelial activation are ...
Alessandra Bettiol1, Giacomo Emmi1, Maria Letizia Urban1, Irene Mattioli1, Federica Bello1   +4 more
core   +1 more source

Long-term efficacy of mepolizumab on eosinophilic granulomatosis with polyangiitis: a retrospective study [PDF]

Exploration of Asthma & Allergy
Aim: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Patients with EGPA are treated with systemic glucocorticoids and immunosuppressive drugs to induce and maintain remission. However, most
Takahiro Matsuyama, Hiromi Matsuyama, Yoichi Dotake, Masashi Oniwa, Kentaro Tsuruzono, Hiroko Uchida, Shunsuke Yasuda, Kiyotaka Kondo, Koichi Takagi, Takayuki Suetsugu, Jun Iwakawa, Kentaro Machida, Keiko Mizuno, Kentaro Tanaka, Hiromasa Inoue   +14 more
doaj   +1 more source